Piper Sandler Sticks to Its Hold Rating for Humacyte (HUMA)
Humacyte Analyst Ratings
Humacyte's Strong Outlook: Buy Rating Affirmed Amid Advancements and Market Opportunity
Buy Rating for Humacyte: Anticipated FDA Approval and Strong Financials Signal Growth Potential
Humacyte Analyst Ratings
Piper Sandler Reaffirms Their Hold Rating on Humacyte (HUMA)
Analysts Offer Insights on Healthcare Companies: Embecta Corporation (EMBC), Mettler-Toledo (MTD) and Humacyte (HUMA)
Buy Rating Justified by FDA Review and Commercial Prospects for Humacyte's HAV Device
Humacyte (HUMA) Gets a Buy From BTIG
Benchmark Maintains Buy on Humacyte, Lowers Price Target to $15
Humacyte Analyst Ratings
Benchmark Co. Sticks to Their Buy Rating for Humacyte (HUMA)
Humacyte Analyst Ratings
Promising Clinical Trials and Innovative Technology Bolster Buy Rating for Humacyte Stock
Piper Sandler Maintains Neutral on Humacyte, Lowers Price Target to $3-Report Released on 9th Nov 2023
Humacyte Analyst Ratings
Buy Rating and Promising Future Prospects for Humacyte: An Analysis
Piper Sandler Sticks to Its Hold Rating for Humacyte (HUMA)
Analysts Are Bullish on These Healthcare Stocks: Century Therapeutics (IPSC), Humacyte (HUMA)
Promising Outlook for Humacyte: Buy Rating Highlighted by Strong Pipeline Progress and Financial Stability
No Data